|
Supplier Glass Vial Defects Prompt Health Canada Warning on Hospira Cancer Drug
Hospira is looking into a supplier glass defect following consumer complaints and a Health Canada warning to physicians not to use three lots of its cancer treatment paclitaxel injection, 300 mg/50 mL.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives